Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-23
Target enrollment:
Participant gender:
Summary
Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effects of treatment on physical function in patients with SCD. The hypothesis to be tested is that anemic SCD patients will have improvements in performance after 6 months of voxelotor treatment.